2013-04-18 00:27:19 - Recently published research from GlobalData, "PharmaPoint: Osteoporosis - Spain Drug Forecast and Market Analysis to 2022", is now available at Fast Market Research
GlobalData has released its new Country report, "PharmaPoint: Osteoporosis - Spain Drug Forecast and Market Analysis to 2022". Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the 'gold-standard' bisphosphonates will lose patent protection by end-of-year 2013, flooding the marketplace with less expensive generic versions of these physician-preferred medications. Additionally, Eli Lilly's blockbuster Evista, the only available SERM in the US, will lose patent protection in 2014, flooding the market with yet more affordable generic options. Also during the forecast period covered by this report, osteoporosis drug development research will lead to the launches of a wave of novel anabolic drugs with greater efficacy and safety, causing a major market shift
away from anti-resorptive drugs. The number of companies vying for patient share will shrink by as much as 50%, as established players exit the market or acquire smaller players. Lastly, the aging of the population in developed markets will result in a larger patient pool.
Full Report Details at
- www.fastmr.com/prod/585864_pharmapoint_osteoporosis_spain_drug_f ..
These changes in the osteoporosis market will be reflected in the slow growth during the forecast period, with the market growing from $6 billion to $8 billion in 2011 USD at a CAGR of 3%.
The large dip in sales caused by these expiries is offset by pipeline product launches over the forecast period, with three of these being potential blockbuster drugs. This next generation of drugs typically consists of biologics and will be higher priced than the drugs losing patent protection in the first half of the forecast period.
* Overview of the Osteoporosis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on the key drugs in Spain including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for the top drugs in Spain from 2012-2022.
* Analysis of the impact of key events as well the drivers and restraints affecting Spain Osteoporosis market.
Reasons to buy
* Understand and capitalize by identifying products that are most likely to ensure a robust return
* Stay ahead of the competition by understanding the changing competitive landscape for Osteoporosis
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
* Make more informed business decisions from insightful and in-depth analysis of drug performance
* Obtain sales forecast for drugs from 2012-2022 in Spain
Partial Table of Contents:
1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2.2 Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.3 Risk Factors
3.1.4 Quality of Life
4 Disease Management
4.1 Treatment Overview
4.1.1 Diagnosis and Referral
4.1.2 Treatment Guidelines
4.1.3 Disease Management
4.2.2 Clinical Practice
5 Competitive Assessment
5.2 Strategic Competitor Assessment
5.3 Product Profiles - Major Brands
5.3.1 Actonel (risedronate sodium)
5.3.2 Evista (raloxifene hydrochloride)
5.3.3 Reclast (zolendronic acid)
5.3.4 Forteo (teriparatide)
5.3.5 Prolia (denosumab)
5.3.6 Protelos (strontium ranelate)
5.3.7 Miacalcin and Fortical (calcitonin-salmon)
5.3.8 Viviant/Conbriza (bazedoxifene)
5.3.9 Recalbon/Bonoteo (minodronic acid hydrate)
5.3.10 Alendronate sodium
6 Opportunity and Unmet Need
6.2 Unmet Needs
6.2.1 Disease Awareness and Early Diagnosis
6.2.2 Patient Compliance
6.2.5 Treatment Cost
6.2.6 Earlier Intervention
6.3 Unmet Needs Gap Analysis
6.4 Opportunity 1: Dual-Action Therapies
6.5 Opportunity 2: Osteoporosis Prevention Therapies
6.6 Opportunity 3: Dosing and Administration
7 Pipeline Assessment
7.2 Promising Drugs in Clinical Development
7.2.1 Aprela (bazedoxifene and conjugated estrogens)
7.2.2 Romosozumab (AMG-785)
7.2.6 Ostora (recombinant salmon calcitonin)
8 Market Outlook
8.1.2 Key Events
8.1.3 Drivers and Barriers
9.4 Forecasting Methodology
9.4.1 Diagnosed Osteoporosis Patients
9.4.2 Percent Drug-Treated Patients
9.4.3 Drugs Included in Each Therapeutic Class
9.4.4 Launch and Patent Expiry Dates
9.4.5 General Pricing Assumptions
9.4.6 Individual Drug Assumptions
9.4.7 Generic Erosion
9.4.8 Pricing of Pipeline Agents
9.5 Physicians and Specialists Included in this Study
9.5.1 About the Authors
Full Table of Contents is available at:
GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at www.fastmr.com/catalog/publishers.aspx?pubid=1015
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at www.fastmr.com
or call us at 1.800.844.8156.